Sjogren Syndrome
Conditions
Interventions
Participants will be randomized (1 to 1 to 1)to Dazodalibep Dose 1, Dazodalibep Dose 2, or placebo as follows.
Experimental: Dazodalibep Dose 1
Participants will be administered dose 1 of dazodalibe
Sponsors
Kawada Ayaka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Key Inclusion Criteria: : Diagnosed with Sjogren Syndrome (SS) by meeting the 2016 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) Classification Criteria. : Have an ESSDAI score of >= 5 at screening despite current or prior symptomatic or local therapy. The following domains will be scored, but they will not contribute to the minimum ESSDAI score of 5 required for inclusion as these domains may have lower sensitivity to change over duration of study: peripheral nervous system, central nervous system, and pulmonary. : Positive for either anti-Ro autoantibodies or rheumatoid factor (RF), or both at screening (as per the central laboratory test).
Exclusion criteria
Exclusion criteria: Key Exclusion Criteria: : Medical history of confirmed deep vein thrombosis, pulmonary embolism, or arterial thromboembolism within 2 years of screening. : Active malignancy or history of malignancy within the last 5 years, except in situ carcinoma of cervix treated with apparent success with curative therapy > 12 months prior to screening OR cutaneous basal cell carcinoma following presumed curative therapy. : Individuals with any severe or life-threatening cardiovascular (including vasculitis), respiratory, endocrine, gastrointestinal, hematological, psychiatric, or systemic disorder or any other condition that would place the individual at unacceptable risk of complications, interfere with evaluation of the IP, or confound the interpretation of participant safety or study results. : Individuals who have a positive test for, or have been treated for, hepatitis B, hepatitis C (unless they have undergone hepatitis C antiviral treatment and have undetectable viral level of hepatitis C RNA at least 24 weeks following completion of therapy) or human immunodeficiency virus (HIV) infection. Active TB or untreated (per local guidelines) latent TB : Individuals with a history of more than one episode of herpes zoster and/or any opportunistic infection in the last 12 months, and active infection requiring systemic treatment at the time of screening or through randomization, or history of more than 2 infections requiring intravenous (IV) antibiotics within 12 months prior to screening. : Individuals who have received a live (attenuated) vaccine within the 4 weeks prior to randomization or plan to receive a live vaccine during their participation in the study. : Last administration of experimental or investigational biologic or oral agents < 6 months prior to screening. : Individuals who have had previous treatment with any biologic B-cell-depleting therapy (eg, rituximab, ocrelizumab, inebilizumab, ofatumumab, or ianalumab) within 12 months or other B-cell-targeting therapy (eg, belimumab) < 3 months prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in ESSDAI score at Week 48 | — |
Countries
Europe, Japan, North, Central and South America, the Asia-Pacific
Contacts
Public ContactAyaka Kawada
CMIC Co., Ltd.
Outcome results
None listed